Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia

Genes and Development

Volumn 28, Issue 12, 2014, Pages 1337-1350

  Liu, Grace J ^a,b   Cimmino, Luisa ^a,b,f   Jude, Julian G ^c   Hu, Yifang ^a   Witkowski, Matthew T ^a,b   McKenzie, Mark D ^a,b   Kartal Kaess, Mutlu ^a,b   Best, Sarah A ^a,b   Tuohey, Laura ^a,b   Liao, Yang ^a,b   Shi, Wei ^a,b   Mullighan, Charles G ^d   Farrar, Michael A ^e   Nutt, Stephen L ^a,b   Smyth, Gordon K ^a,b   Zuber, Johannes ^c   Dickins, Ross A ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B ALL; Differentiation; Leukemia; PAX5; Transcription factor

Indexed keywords

CD19 ANTIGEN; STAT5 PROTEIN; TRANSCRIPTION FACTOR PAX5;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; GENE; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PAX5 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

B-ALL; DIFFERENTIATION; LEUKEMIA; PAX5; TRANSCRIPTION FACTOR;

ANIMALS; B-CELL-SPECIFIC ACTIVATOR PROTEIN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, MYC; HUMANS; MICE; MICE, TRANSGENIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELLS, B-LYMPHOID; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 84902504214     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.240416.114     Document Type: Article

References (53)

1. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. 2012. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
2. + memory T cells. J Immunol 171: 5853-5864.
3. Cobaleda C, Schebesta A, Delogu A, Busslinger M. 2007. Pax5: the guardian of B cell identity and function. Nat Immunol 8: 463-470.
4. Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M. 2006. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity 24: 269-281.
5. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Lowe SW. 2005. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 37: 1289-1295.
6. Dorfler P, Busslinger M. 1996. C-terminal activating and inhibitory domains determine the transactivation potential of BSAP (Pax-5), Pax-2 and Pax-8. EMBO J 15: 1971-1982.
7. Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, et al. 2010. BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med 207: 1209-1221.
8. Grawunder U, Leu TM, Schatz DG, Werner A, Rolink AG, Melchers F, Winkler TH. 1995. Down-regulation of RAG1 and RAG2 gene expression in preB cells after functional immunoglobulin heavy chain rearrangement. Immunity 3: 601-608.
9. Habib T, Park H, Tsang M, de Alboran IM, Nicks A, Wilson L, Knoepfler PS, Andrews S, Rawlings DJ, Eisenman RN, et al. 2007. Myc stimulates B lymphocyte differentiation and amplifies calcium signaling. J Cell Biol 179: 717-731.
10. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. 1991. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 173: 1213-1225.
11. Heltemes-Harris LM, Willette MJ, Ramsey LB, Qiu YH, Neeley ES, Zhang N, Thomas DA, Koeuth T, Baechler EC, Kornblau SM, et al. 2011. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med 208: 1135-1149.
12. Herzog S, Reth M, Jumaa H. 2009. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol 9: 195-205.
13. Hoffmann R, Seidl T, Neeb M, Rolink A, Melchers F. 2002. Changes in gene expression profiles in developing B cells of murine bone marrow. Genome Res 12: 98-111.
14. Inaba H, Greaves M, Mullighan CG. 2013. Acute lymphoblastic leukaemia. Lancet 381: 1943-1955.
15. Kawamata N, Pennella MA, Woo JL, Berk AJ, Koeffler HP. 2012. Dominant-negative mechanism of leukemogenic PAX5 fusions. Oncogene 31: 966-977.
16. Kim WI, Wiesner SM, Largaespada DA. 2007. Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cells. Exp Hematol 35: 1231-1239.
17. Kuiper RP, Schoenmakers EF, van Reijmersdal SV, Hehir-Kwa JY, van Kessel AG, van Leeuwen FN, Hoogerbrugge PM. 2007. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 21: 1258-1266.
18. Kumagai M, Coustan-Smith E, Murray DJ, Silvennoinen O, Murti KG, Evans WE, Malavasi F, Campana D. 1995. Ligation of CD38 suppresses human B lymphopoiesis. J Exp Med 181: 1101-1110.
19. Law CW, Chen Y, Shi W, Smyth GK. 2014. Voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 15: R29.
20. Liao Y, Smyth GK, Shi W. 2013. The subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res 41: e108.
21. Liao Y, Smyth GK, Shi W. 2014. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30: 923-930.
22. Mackay F, Figgett WA, Saulep D, Lepage M, Hibbs ML. 2010. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 237: 205-225.
23. Malin S, McManus S, Busslinger M. 2010. STAT5 in B cell development and leukemia. Curr Opin Immunol 22: 168- 176.
24. Mangum DS, Downie J, Mason CC, Jahromi MS, Joshi D, Rodic V, Muschen M, Meeker N, Trede N, Frazer JK, et al. 2014. VPREB1 deletions occur independent of l light chain rearrangement in childhood acute lymphoblastic leukemia. Leukemia 28: 216-220.
25. + stage. Eur J Immunol 34: 2647-2655.
26. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, et al. 2007. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446: 758-764.
27. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui C-H, et al. 2008. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453: 110-114.
28. Nakayama J, Yamamoto M, Hayashi K, Satoh H, Bundo K, Kubo M, Goitsuka R, Farrar M, Kitamura D. 2008. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. Blood 113: 1483-1492.
29. Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA, Strehl S. 2009. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23: 134-143.
30. Nutt SL, Kee BL. 2007. The transcriptional regulation of B cell lineage commitment. Immunity 26: 715-725.
31. Nutt SL, Urbanek P, Rolink A, Busslinger M. 1997. Essential functions of Pax5 (BSAP) in pro-B cell development: difference between fetal and adult B lymphopoiesis and reduced V-to-DJ recombination at the IgH locus. Genes Dev 11: 476-491.
32. Nutt SL, Heavey B, Rolink AG, Busslinger M. 1999. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401: 556-562.
33. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM. 2012. BET bromo-domain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 120: 2843-2852.
34. Pelengaris S, Khan M, Evan G. 2002. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2: 764-776.
35. Premsrirut PK, Dow LE, Kim SY, Camiolo M, Malone CD, Miething C, Scuoppo C, Zuber J, Dickins RA, Kogan SC, et al. 2011. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145: 145-158.
36. Pridans C, Holmes ML, Polli M, Wettenhall JM, Dakic A, Corcoran LM, Smyth GK, Nutt SL. 2008. Identification of Pax5 target genes in early B cell differentiation. J Immunol 180: 1719-1728.
37. Revilla-I-Domingo R, Bilic I, Vilagos B, Tagoh H, Ebert A, Tamir IM, Smeenk L, Trupke J, Sommer A, Jaritz M et al. 2012. The B-cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis. EMBO J 31: 3130-3146.
38. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, et al. 2012. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22: 153-166.
39. Rolink A, Grawunder U, Winkler TH, Karasuyama H, Melchers F. 1994. IL-2 receptor a chain (CD25, TAC) expression defines a crucial stage in pre-B cell development. Int Immunol 6: 1257-1264.
40. Rolink AG, Nutt SL, Melchers F, Busslinger M. 1999. Long-term in vivo reconstitution of T-cell development by Pax5-de-ficient B-cell progenitors. Nature 401: 603-606.
41. Rolink AG, Winkler T, Melchers F, Andersson J. 2000. Precursor B cell receptor-dependent B cell proliferation and differentiation does not require the bone marrow or fetal liver environment. J Exp Med 191: 23-32.
42. Schaniel C, Gottar M, Roosnek E, Melchers F, Rolink AG. 2002. Extensive in vivo self-renewal, long-term reconstitution capacity, and hematopoietic multipotency of Pax5-deficient precursor B-cell clones. Blood 99: 2760-2766.
43. Schebesta M, Pfeffer PL, Busslinger M. 2002. Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. Immunity 17: 473-485.
44. Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. 2007. Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function. Immunity 27: 49-63.
45. Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, Wechsler J, Yang J, Hayes J, Klein RJ, et al. 2013. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet 45: 1226-1231.
46. Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, et al. 2013. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med 19: 1014-1022.
47. Takiguchi M, Dow LE, Prier JE, Carmichael CL, Kile BT, Turner SJ, Lowe SW, Huang DC, Dickins RA. 2013. Variability of inducible expression across the hematopoietic system of tetracycline transactivator transgenic mice. PLoS ONE 8: e54009.
48. Thompson EC, Cobb BS, Sabbattini P, Meixlsperger S, Parelho V, Liberg D, Taylor B, Dillon N, Georgopoulos K, Jumaa H, et al. 2007. Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. Immunity 26: 335-344.
49. Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, et al. 2009. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med 206: 1739-1753.
50. Urbanek P, Wang ZQ, Fetka I, Wagner EF, Busslinger M. 1994. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/ BSAP. Cell 79: 901-912.
51. van Loo PF, Dingjan GM, Maas A, Hendriks RW. 2007. Surrogate-light-chain silencing is not critical for the limitation of pre-B cell expansion but is for the termination of constitutive signaling. Immunity 27: 468-480.
52. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. 2013. Cancer genome landscapes. Science 339: 1546-1558.
53. Wu D, Lim E, Vaillant F, Asselin-Labat M-L, Visvader JE, Smyth GK. 2010. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics 26: 2176-2182.